Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

10 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

GIA, GIACONDA LIMITED
wallyoff
post Posted: Mar 13 2014, 07:08 PM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: mongoose's post @ Jan 15 2014, 06:24 AM

Off we go. Giaconda has received $1 million upfront payment for Picoconda.

Looks like thing may be looking up the year for long suffering shareholders.

Also, Giaconda has a new website http://www.giacondaltd.com/

http://www.giacondaltd.com/uploads/3/3/1/3/3313979/270214_announcement.pdf

Sydney, NSW, [28 February] 2014 - Giaconda Limited ("Giaconda") today announced that RedHill

Biopharma Ltd ("RedHill" ; NASDAQ: RDHL) has entered into a worldwide license agreement with Salix Pharmaceuticals for Picoconda and rights to other purgative developments. Giaconda sold Picoconda to RedHill under an asset purchase agreement along with its proprietary products Myoconda and Heliconda in 2010. Giaconda will receive an upfront payment of US$1,000,000 plus 20% of the net royalties paid to RedHill by Salix. In addition, Giaconda will receive 20% of future milestones.





--------------------
“If you want to get something done, always ask the busiest person”
 
mongoose
post Posted: Jan 15 2014, 06:24 AM
  Quote Post


Posts: 369
Thanks: 19


In Reply To: wallyoff's post @ Dec 29 2013, 09:33 AM

Thanks for that update, much appreciated


 
wallyoff
post Posted: Dec 29 2013, 09:33 AM
  Quote Post


Posts: 53
Thanks: 7


It’s been a few years since there were any posts on Giaconda. I believe that Giaconda shareholders are overdue for an update.

I have sent the CEO of Giaconda Mr Patrick Mclean an e-mail regarding the future of Giaconda. I won’t be copying and pasting the e-mail as to do so will be I believe that is in bad taste and a breach of trust. Below is some information in his e-mail.

The Bad News

Giaconda has been delisted from the ASX since August 2013 and according to Patrick Mclean Giaconda will not be relisting on the ASX. He said that in the future it may relist as who knows what will happen in the next 2-3 years.

Giaconda will be a cashbox company relying on patent royalties payments. According to Patrick the ASX doesn’t like cashbox companies as Giaconda don't have resources to acquire and develop new drugs. (I thought that was the original business plan for the company)

The Good News

As in my previous post Giaconda was placed into voluntary administration. Patrick said in his e-mail that Giaconda is now out of administration. This hasn’t been announced to shareholders. Professor Thomas Borody is now helping with funding.



Enter Redhill Biopharma

Name changes by Redhill Biopharma for Myoconda, Heliconda and Picoconda

  • Myoconda now RHB-104
  • Heliconda now RHB-105
  • Picoconda now RHB-106


The Jewel in the Crown Myoconda or RHB-104

Myoconda or RHB-104 has some other drug uses other than Crohn's disease

[/size]

[size="3"]
As you can see in the above table Myoconda can do more than help suffers with Crohn's disease.. Just remember that all of the above mentioned Multiple Sclerosis, Rheumatoid Arthritis and Lupus have not been approved and for use and are year away from being approved by the FDA.




Redhill Biopharma Presentation November 2013

http://files.shareholder.com/downloads/AMDA-1C0OBF/2864247607x0x701379/47f45d13-4711-4d3c-9180-c3ecef3aac0b/RedHill%20Biopharma%20Presentation%20November%202013.pdf



Myoconda and Crohn's disease

http://bio-associate.blogspot.com.au/2013/04/redhill-biopharma-valuation-report-by.html?m=1

Crohn's disease (CD) is part of a family of inflammatory bowel diseases (IBD), which also includes ulcerative colitis and indeterminate colitis. All IBD-related pathologies are associated with intestinal inflammation, resulting from uncontrolled inflammatory processes in the gastrointestinal (GI) tract lining, which involves the attack of the tissues by the body's own immune system.



At present, CD is considered a result of multifactorial causes, including genetic, immune-related, environmental, and infectious triggers. Among the infectious triggers, the Mycobacterium avium subspecies paratuberculosis (MAP) bacterium is considered as a major contributing factor for a significant sub-population of Crohn's disease patients.





In 2011, Crohn's disease prevalence in the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK) was approximately 900,000 diagnosed patients, over half of which were in the US. The 2010 global Crohn's disease therapeutics market was estimated at $3.6 billion. Conventional treatment is directed almost exclusively at suppressing the inflammatory processes, although the dysregulation of the immune system is likely secondary to the disease's actual trigger

RedHill's RHB-104 is a patented combination of three generic antibiotic agents - clarithromycin, clofazimine and rifabutin, in a single capsule, for the treatment of MAP infections in Crohn's disease. This treatment's rationale is based on the assumption that CD, at least in some patients, is caused by the presence of MAP bacterium. The drug is currently developed for treatment of moderate-to-severe active Crohn's disease in adults. However, RedHill obtained an FDA Orphan Drug status for RHB-104 for the treatment of CD in the pediatric population, and is likely to pursue a regulatory approval for this population. RHB-104 was acquired by RedHill in 2010 from Giaconda Ltd. In 2011, RedHill acquired the exclusive rights to a patented diagnostic test for the identification of the presence of MAP bacteria in patients. Later on, RedHill entered into an agreement with Quest Diagnostics to develop a commercial diagnostic test for MAP bacteria DNA in the blood, based on the acquired technology. Based on data analysis of a Phase III study, performed by Giaconda in Australia, RedHill is currently preparing two pivotal Phase III studies with RHB-104 for the treatment of moderate-to-severe active Crohn's disease. The first study (in North America and Israel) is expected to begin in Q2 2013, and we estimate that the European study will begin during Q1 of 2014. We embrace the company's assumptions relating to the costs of these studies at $14 million. Upon success in these studies, we estimate regulatory submission during 2016 and market launch during 2017. The CD therapeutics pipeline is robust and varied, with several first-in-class molecules in late-stage clinical development (table 2). The launch of those products is expected to balance the anticipated arrival of several generic/biosimilar drugs (mainly for Entocort EC and Remicade) and expand the current market

Unlike its pipeline competitors, RHB-104 is not an anti-inflammatory agent. This differentiation from the bulk could be an advantage, should this drug candidate prove to be efficient in inducing disease remission without safety issues. However, the different mechanism of action of RHB-104, and the fact that its relation to CD is not widely accepted in the scientific community, could interfere with the drug's commercial potential, if clinical efficacy will not be remarkable. RHB-104's target market is based on the current Crohn's Disease therapeutics market. However, we assume that the actual addressable market for RHB-104 will be smaller (~1.8 billion) due to the therapy's relevance only to MAP-positive patients (~50% of patients), high estimated treatment price (~$8000 per patient per year) and presumed adoption as a second or third line of treatment. We estimate a maximal penetration rate of 30% to the immediate addressable market.



First Patient Dosed with Myoconda for Trials

http://www.redhillbio.com/wp-content/uploads/2013/11/RedHill-Biopharma-Announces-First-Patient-Dosed-in-Phase-III-Study-of-RHB-104-for-Crohns-Disease.pdf



  • First patient has been recruited and dosed in the MAP US study - a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the safety and efficacy of RHB-104 for treatment of Crohn's disease


  • The Phase III study is expected to enrol 240 subjects in over 50 clinical sites in the U.S., Canada and Israel. Subjects will be treated for 52 weeks with a primary endpoint of remission at week 26


  • An independent data and safety monitoring board (DSMB) will perform a futility analysis when half the subjects complete the first 26 weeks of blinded treatment
Heliconda RHB-105

Helicobacter pylori (H. pylori) is a gram-negative bacterium that lives in the stomach and duodenum, and is the major cause of peptic ulcer disease in the stomach and duodenum (14 million Americans), as well as of gastric ulcer cases (21,000 new cases per year in the US). 30% of the population in developed countries and 80% in developing countries are infected with H. Pylori. However, treatment for the eradication of the bacteria is almost always performed only upon occurrence of an associated pathology. International guidelines for first-line H. Pylori eradication recommend a triple combination of a proton pump inhibitor ("PPI" - a class of drugs that inhibit the stomach's proton pumps and induce reduction of gastric acid production) and two of three antibiotics (usually amoxicillin, clarithromycin or metronidazole). These medication combinations typically cure about 70-80% of infections, with antibiotic resistance being the primary cause of therapeutic failure. RedHill's RHB-105 is an orally administered combination of three approved drugs: omeprazole (a proton pump inhibitor) and amoxicillin and rifabutin, which are antibiotic agents. Rifabutin (RedHill's alteration to the current drug combination) has potential utility against H. Pylori based on the very low prevalence rate of rifabutin resistance, as well as clinical and pre-clinical efficacy data. RedHill plans to initiate a Phase II/III study with RHB-105 in North America during the first quarter of 2013. We estimate that top-line results from this study will be published by the end of 2013. Should this study be successful, we anticipate an additional Phase III study to be conducted during 2014, prior to an NDA submission during 2015. Market launch is expected during 2016 in the US, and 2017 in non-US markets. The clinical pipeline for H. Pylori eradication therapies is lean, and comprised mostly of new antibiotic agents in mid-stage clinical development (table 4). Examples of such novel antibiotics include Sequella's SQ109, ActivBiotics' Rifalazil and MerLion's Finafloxacin. Non-antibiotic therapies are in earlier stages of development: anti-H. Pylori vaccines are developed by 2-3 companies, but all products are in pre-clinical stages. In the near future, no major changes are expected in the current H. Pylori eradication guidelines. The insufficient and constantly declining success rates of current treatments, due to antibiotic resistant strains, pose an opportunity for the introduction of new medicine combinations. In this ecosystem, RHB-105 is the only late-stage drug candidate. RHB-105's target market was calculated based on several assumptions: (1) we estimate this drug will be used as a second or third line of therapy; (2) price per treatment for RHB-105 was assumed to be $550 per patient, reflecting a 20% premium over pre packaged combination products; (3) low penetration rates are predicted in developing countries due to price premium over generic alternatives. We estimate a maximal share of 7.5% to the calculated addressable market, representing annual peak sales of approximately $300 million. In addition to the specified market parameters, the patent family for RHB-105 is set to expire during 2019. According to our estimations, this will result in only 4 years of market exclusivity for RHB-105 before it will be susceptible to direct competition. The valuation of RHB-105 is a risk-adjusted net present value (rNPV) capitalization to the net present value. The valuation includes weighting of several scenarios, based upon main assessments described above. The valuation parameters are summarized in table History Lesson in GIA!

In August 2010 Giaconda sold Myoconda, Heliconda and Picoconda patents to Redhill Biopharma based in Israel for US $500,000 (7% of net sales earned by Redhill and 20% of sublicense receipt will be going to Giaconda).



http://www.giacondaltd.com/uploads/3/3/1/3/3313979/disclosure_document_-_red_hill_sale.pdf



Some Questions, need Help!

What will be the dividends that will be paid in the distant future? Sorry I have no idea how much a per share dividend will be paid when (Myoconda with Crohn's disease) and (Heliconda RHB-105 Helicobacter pylori) .Some reports are saying US 1.8 Billion for Myoconda and for Heliconda US300 Million (see below links). Yea sure, I can get 7% of 2.1 Billion = US 147 million (Is this correct, or am I dreaming?)

Well it looks like we won’t be able to sell the share in Giaconda in the near future. How can we sell our shares if we want to? Personally I don’t want to sell the shares as I believe the royalties could be significant to Giaconda and share holders.



Summing up

Well it’s going to be years until Giaconda receives a royalty payment for Myoconda 2016 and Heliconda 2015. http://www.bioassociate.com/redhill-biopharma-ltd-initiation-of-coverage/



The CEO said that the dividends will more than reward share holders in the future (he could be correct!)

We have waited this long so what another few more year



Wally





--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: fraz2  
 
wallyoff
post Posted: Feb 28 2011, 08:47 PM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: wallyoff's post @ Dec 5 2010, 10:48 AM

Invisible Ink from Directors
As a shareholder of Giaconda I’m in shock of the company going into ‘Voluntary Administration’. The directors said in many ASX announcements that they will help finance Giaconda. Sorry I can’t read invisible ink, directors now not supporting Giaconda financially, no announcement to ASX.


The Invisible Ink

Looks like we have been mislead to from the current soon to be disgraced CEO Mr. Patrick McLean and directors. In a previous announcement dated 30/11/2010 ‘Chairman`s Address to Shareholders - 2010 AGM’ (not on the Giaconda Limited website, strange) http://www.giacondalimited.com/pages/investor/asx_press_release.html

Web link from the ASX website.

http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=GIA&timeframe=D&period=M6

Quoting from page 8 eight from the Power Point presentation

I think that the amount of personal funds that the Directors have lent to the company says something about our commitment to and belief in what we are doing. I see and treat patients every day with some of the therapies that have been put under the wing of Giaconda and know firsthand what they can do. The original goal of setting up the Company was to get these therapies to patients around the world and we have made great progress.



But, it has taken more money than we originally planned and that money had to come from somewhere. So the Directors, Trevor, Chris, Patrick and I dug deep into our own pockets to help keep the progress going. Together we put in $280,000 dollars

Myoconda can still save Giaconda

I believed that this was going to be the year of Giaconda when all the directors’ hard work and money would have paid off. The sale to Redhill Biopharma was and still is a great leap for Giaconda, there main drug will be Myoconda. Myoconda should be approved by the FDA in less than 12 months if all goes well.

The FDA has a special Fast Track Development Program; Myoconda does fall into this category.

From Wikipedia.com

“The FDA Fast Track Development Program is a designation of the United States Food and Drug Administration (FDA) that accelerates the approval of investigational new drugs undergoing clinical trials. Such status is often given to agents that show promise in treating serious, life-threatening medical conditions for which no other drug either exists or works as well.

http://en.wikipedia.org/wiki/FDA_Fast_Track_Development_Program

As stated before Myoconda should be worth approx 140 Million US$ in sales royalties to Giaconda (very optimistic but realistic approx minimum 70 million US$ per year.) Please see my old postings.


Myoconda Estimate sales $US $2B x 7% Sales =140

Heliconda Estimate sales $US $150M x 7% Sales =10.5

Picoconda Estimate sales $US $245M x 7% Sales =17


Total=$US $167.5M


If Myoconda is approved is a quick fashion this will save the company.

Redhill Biopharma

Patrick McLean is working for Redhill as a Product Manager at Redhill Biopharma. Seems very strange that Patrick McLean is working for the same drug company that Giaconda sold its three main drugs to (MYOCONDA, HELICONDA AND PICOCONDA). Nowhere has there been an announcement to the ASX on Mr Patrick Mclean working for Redhill. By no means am I’m I saying that there is anything underhanded in working for Redhill just strange that no announcement(s) have been made available to shareholders (maybe he doesn’t have to! But seems very strange as this should have been a positive announcement for Giaconda). If Patrick was working for Giaconda shareholder interest Redhill Biopharma would have made an announcement on any of their three drugs purchased from Giaconda in the past six months. IF Patrick is working for Giaconda shareholders there should be an announcement soon from Redhill as there has been no update from Redhill and Giaconda since the sale to Redhill, very strange.

http://www.redhillbio.com/about-redhill/team/

Redhill Biopharma TASE Update link (in Hebrew) just use Google Translate to covert Hebrew to English, ………easy.

http://maya.tase.co.il/bursa/index.asp?view=search&company_group=3001&srh_comp_lb=1573&srh_from=2010-08-28&srh_until=2011-02-28&srh_anaf=-1&srh_event=9999&all_reports=1

Voluntary Administration

Below is a link on how a voluntary Administration works in Australia.

http://www.bankruptcy.net.au/docs/VoluntaryAdministrations.pdf

The administration period is typically only 25 business days.

Summary of Process



1st Business Day: Appointment of administrator

The administrator takes control of company.

Directors’ powers cease and liability for insolvent trading ends.

Moratorium on creditors’ claims imposed.



8th Business Day: 1st meeting of creditors

Creditors confirm appointment of incumbent administrator or replace the incumbent

administrator with another.



18th Business Day: Report by administrator issued

Disclosure of investigations and viability of rescue plan, if proposed.



25th Business Day: 2nd meeting of creditors

Creditors determine company’s future.

Future of Giaconda

I feel the company has a strong future as long as the Administrators / Directors don’t go stupid with cash. The present IDIOT directors spent the following forcing the company to go into Administration.

Taken from Half Yearly Report

Personnel $16,010

Finance and legal $176,417

Administration $63,566

Research and development $74,364



Take out Finance and Legal and R&D the debt would have been $251,000 less. What the hell did they spend $176,000 on in Finance and Legal? And R&D $74,000 . To show how stupid the directors are. The directors spent over $2,800.00 per week on R&D. This is really stupid considering that the company is strictly short on cash. (Should have halted the R&D!!!)



A big question mark over Finance and legal at $176,000. What the hell did there directors do to see a bill of that amount? Auditors should be asking questions to the directors on this one?



The company could be still trading considering if the directors had some cash to help the company. Now the company could go into liquidation (don’t know what’s to buy considering as the drug patents have been sold to Redhill) Unless REDHILL purchases the royalties from Administrator that would raise a few eyebrows in Australia.



I’m still wondering as many other Giaconda shareholders when Giaconda survived the GFC in 08 cannot survive the best chance of making Giaconda a great company. I feel there is another agenda on the horizon for this company as the directors appear to want to place the company into Administration and liquidate the company. Only time will tell, prove me wrong.





Sorry for all shareholders who own this stock, looks like we have been shafted by the directors.



Wally













--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: fraz2  
 
wallyoff
post Posted: Dec 5 2010, 10:48 AM
  Quote Post


Posts: 53
Thanks: 7


AGM – Giaconda 2010 a Better Year for 2011

Another year has passed and this company has survived the worst of the GFC thanks to directors financing this pass year and $500,000.00 from Redhill Biopharma.

As in my previous posts Giaconda has turned a significant corner with future development of the three main drugs. MYOCONDA, HELICONDA and PICOCONDA. The company will be developing these 3 drugs in the final stage is called is called Redhill Biopharma which is based in Israel.

Redhill lead product will be Myoconda 1 and according the CEO of Giaconda they are going ‘full steam ahead’ and ‘have already started testing’. According to the CEO of Giaconda Myoconda will be approved in 18 months to 2 years. This should be the start of big things for Giaconda. As Giaconda business plan was to sell the drugs Intellectual Property (IP) and retain a royalty.

Other questions asked were about ‘any new drugs in development?’ Apparently with drug development other cures can/could be found. Such as with the development of Ibaconda the base drug is ‘Olsalazine is an anti-inflammatory’ 2. (This drug Olsalazine could be treating IBS in the future) and Ibaconda could be treating some other disease for example such as bowel cancer…….don’t know what?. (Don’t get your hopes up with Ibaconda it’s many, many, and many……….. years away from being approved)

Also Giaconda will be getting a Twitter account and a Facebook page. Seems kind of silly but this is the future for marketing and keeping interest in the drug development on Myoconda and future drugs. One gentleman at the AGM stated that a NSW Government Dep’t has 100,000 followers on Twitter and many drug companies are utilising this new FREE media (so not so silly).

REDHILL BIOPHARMA

Redhill has raised 10 Million Dollars from Private Investors 3 Originally Redhill only required to raise 3 Million Dollars (I’m assuming that it is in US$). Redhill could be listed on the Israel stock exchange in the future according to many websites ‘we are examining the possibility of an IPO on the Tel Aviv Stock Exchange’ 4 If listed I don’t think much will change with Giaconda.

The Future for Giaconda

This company has been a disappointment in the pass with a dwindling share price. But with Directors willing to support the company with financing the company now has strong future.

I personally would like to see more announcements from Giaconda on the actual start date of the clinical trial and what Redhill are actually doing! If this happens I feel that there will be more confidence with investors and share price will increase. Last update on a drug was 9/7/2008.

Giaconda shares are tightly held and very few shares are traded weekly /monthly. As stated before Giaconda top 20 own approx 85% (In the top 5 of the ASX of tightly held stock). Since the shares are so tightly held share price could jump very high very quickly as it happened this week (up 30% on low volume)

When Myoconda is approved the share price will not be under a $1.00 due to a very tight a shareholding.

Wallly




1. http://technews.tmcnet.com/news/2010/11/04/5117524.htm

(Lead Product 5th Parra graph)

2. http://www.giacondalimited.com/pages/products/iba_conda.html (5th Paragraph)

3. http://www.vcaonline.com/news/news.asp?ID=2010110804 ( Investment- Headline)

4. http://au.finance.yahoo.com/news/RedHill-Biopharma-Raises-35M-bw-2252113904.html?x=0 (5th Paragraph)









--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: fraz2  
 
wallyoff
post Posted: Sep 4 2010, 08:06 AM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: wallyoff's post @ Aug 17 2010, 09:07 AM

<H1 style="MARGIN: 10px 40px 15px 0px; FONT-FAMILY: arial; FONT-SIZE: 24px; FONT-WEIGHT: 700">RedHill Biopharma raises $3.5m ahead of IPO</H1>
RedHill has signed a co-development and commercialization agreement for IntelGenx' first oral thin film anti-migraine product.
31 August 10 16:22, Batya Feldman</SPAN>RedHill Biopharma Ltd. has raised $3.5 million in a private round of funding. The company plans raising an additional $2 million in the coming weeks ahead of an IPO on the Tel Aviv Stock Exchange (TASE) in early 2011.

RedHill, which was founded in 2009 by Belgium-based ProSeed Capital Holdings, develops and commercializes treatments and products in advanced stages of clinical trials.

RedHill yesterday announced that the company had signed a co-development and commercialization agreement for IntelGenx' first oral thin film product based upon the IntelGenx' proprietary VersaFilm technology. The product is intended for the rapid relief of migraine. RedHill has previously paid several million shekels to Australia's Giaconda for a Crohn's disease treatment and two treatments for digestive problems. The Crohn's disease treatment is the most advanced of these treatments and is already in the Phase III clinical trials for US Food and Drug Administration

Source: http://www.globes.co.il/serveen/globes/doc...51&fid=1725





--------------------
“If you want to get something done, always ask the busiest person”
 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


wallyoff
post Posted: Aug 17 2010, 09:07 AM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: wallyoff's post @ Jun 22 2010, 10:57 PM

Best News Ever for Giaconda --- Off we Go!

Today’s announcement from Giaconda’s CEO Mr. Patrick McLean was the best news Giaconda has had for literally years. Being a shareholder of this tightly held Bio, this will be the start of bigger and better things to come.




The news is something that the Giaconda hasn’t seen for years, CASH! $US500, 000. This cash injection will help Giaconda develop the drug Ibaconda which is a more marketable drug than Myoconda. (‘Ibaconda’ - A combination therapy for Irritable Bowel Syndrome Constipation-predominant Irritable Bowel Syndrome’)



I noticed that in last year’s ‘Annual Report to shareholders’ on 23/10/2009 on page 8 that ‘The Centre for Digestive Diseases’ will be Planning of the first Phase II clinical study on the use of Ibaconda for the treatment of constipation predominant irritable bowel syndrome.



From the Annual Giaconda Report



Ibaconda®

Planning of the first Phase II clinical study on the

use of Ibaconda for the treatment of constipation

predominant irritable bowel syndrome (C-IBS)

continued during the period. This study is now

anticipated to begin in 2010 at The Centre for

Digestive Diseases subject to available funds. A

scientific poster on the combination was presented

at the Digestive Disease Week conference in June,

2009.





I believe that Giaconda has already started the ‘first Phase II clinical study on Ibaconda’. The reason is that in the last ‘Disclosure Document - 4C for FY10’ dated 2/08/10. I noticed that in the report the ‘research and development’ was $36,000. While in the ‘Appendix 4C - quarterly’ on 3/5/10 ‘research and development’ was only $8,000. I’m not saying that the money spent on ‘research and development’ was spent on developing Ibaconda. But the question is what was the money spent on? I don’t think the CEO would allow the money to be spent on other drugs when they were offloading them to Redhill. If this is the case expect an announcement on the advancement of Ibaconda soon.



According to the ‘Annual Report to shareholders’ on 23/10/2009 on page 4 there are 466 million sufferers of ‘Irritable Bowel Syndrome’. The potential future sales for Ibaconda from a Power Point presentation is > 500 Million (from Thursday 27 November 2008 AGM Presentation). This would appear to be the CEO’s center of attention for Giaconda.



Redhill Biopharma

I feel that Redhill will be pushing for an early as possible release for Myoconda. Why! The drug is at the last stage of development and Redhill a will be newly listed company on the Israel stock exchange so shareholders want some action on their expensive purchase. I hope Giaconda receives royalty payments soon.





Future Share Prices
The top 20 share holders which have 85.2% of the stock last year. This year it is 85.4% of the shares (one of the most tightly held shares in the ASX) it would not take much to see the share price move quickly with a good Ibaconda development announcement. Looking at the share price of just $00.05c and little share low liquidity it would not take much to see an increase in the share price. For example Giaconda gained 116.7% (+7c) to 13c over in a week, and while only 190,900 shares were traded in all In September 09.



Summing up

Just need to have some sort of timeline from Giaconda on Ibaconda and Redhill on Myaconda of drug developments.



  • When will they be going on the market?
  • Who will market the drug(s)?
  • Who will distribute the drug(s)?




I feel that the future of Giaconda is with Ibaconda with 1/2 a billion $US in potential sales. Considering Giaconda market value is now at 2.3 Million. With future sales this current share price will be a distant memory if/when approved.



If you think the share price is going to remain low think again as stated above, not many shares don’t get traded in this stock a good announcement will send the share price in a rapid rise.



Wally



Yes, I own this stock (plenty)!







--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: fraz2  
 
wallyoff
post Posted: Jun 22 2010, 10:57 PM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: wallyoff's post @ Mar 16 2010, 08:06 PM

Positive Good News ….Finally



Giaconda has announced the sale of Myoconda, Heliconda, and Picoconda to Red Hill Biopharma Ltd of Israel. The three drugs have been sold for a total $US $500,000 plus a 7% of net sales received.



To say that the deal is great for Giaconda shareholders is a bit, yes great and not so great. I’m not in high spirits with the three drugs being sold for such a discounted price. I was expecting much more than $US 500,000. “Beggars can not be choosey” considering Giaconda financial position.



Red Hill Biopharma

I have been trying to find some background on Red Hill Biopharma Ltd of Israel. Not much shows up in a quick Google search. It would appear that Red Hill will be listed on the Israel stock exchange at the end of the year. *1



News about the Myoconda sale to Red Hill was from an Israel website



RedHill Biopharma buys digestive system drugs rights *2



AMTI

In some ways this deal with Red Hill is better than the FAILED AMTI deal. I have no idea why the current CEO has been dealing with is un-reliable, and my I add unknown company. AMTI wanted to invest in Giaconda on 18th July 2008 and failed to come up with the funds. AMTI failed again to raise funds in June 2010.



*3 --Page 1

The last deal would have seen AMTI with 17,000,000 Giaconda shares purchased at $00.06.5c per share and a royalty payment of only 5% of net sales received. This would have seen AMTI holding approx %25 to %30 of Giaconda shares. The new deal with Red Hill Biopharma Ltd has no share issued and no options pending. This will not dilute the shares of Giaconda.





Projected Estimate Sales from Red Hill Biopharma

Here is an estimate of projected sales of the 3 drugs sold to Red Hill Biopharma. I’m taking the sales figures from an old AGM Power Point presentation which was presented in late November 2008. All the below drugs have not been approved by the FDA and will naturally need approval before going on sale. According to the CEO Myoconda will take 12 months to be approved.



*4

Myoconda Estimate sales $US $2B x 7% Sales =140

Heliconda Estimate sales $US $150M x 7% Sales =10.5

Picoconda Estimate sales $US $245M x 7% Sales =17

Total=$US $167.5M



The 167 million will need to be converted to $AU dollars this will be $AU190M at current exchange rate of .087. Remember this is an extremely optimistic future sales guide from a Power Point presentation years ago. (I have nothing else to work with!)





Future Share Prices
Giaconda is one of the most tightly held shares in the ASX. I believe it to be in the top 5 of the ASX tightly held stock, the top 20 share holders have 85.2% of stock. Giaconda has only 77,436,005 shares listed. To prove how tightly held this stock is only $117,288 has been traded or 2,001,886 shares in 12 Months as of 22 June, 2010. *5.

The current value of this stock is $00.03 per share. With a Market Capitalisation of $2,323,080 this stock is way under valued but to future potential sales as stated in future sales.



At the moment Giaconda has little or no money and soon as this sale has gone threw to Red Hill we should see an improvement in the share price immediately. In my last post I stated that Giaconda last drug not to be sold to Red Hill is ‘Ibaconda’ (treatment of irritable bowel syndrome) with an estimate sales of +$US500.



In a quick summing up Giaconda has a brighter future and looks like the Red Hill deal is great for shareholders.



Wally

[/size]

[size="3"]




Source

*1

http://www.thepharmaletter.com/file/94819/ahead-of-an-ipo-israels-redhill-biopharma-likely-to-raise-5-million-privately-says-globes.html



*2

http://www.globes.co.il/serveen/globes/docview.asp?did=1000568581&fid=942



*3

http://www.asx.com.au/asxpdf/20100309/pdf/31p4yxsd6wj7p0.pdf



*4

http://www.giacondalimited.com/pdfs/AGM%20presentation.pdf



*5

http://www.tradingroom.com.au/apps/qt/quote.ac?section=tradesum&sy=tpl&code=GIA#tabs





--------------------
“If you want to get something done, always ask the busiest person”
 
wallyoff
post Posted: Mar 16 2010, 08:06 PM
  Quote Post


Posts: 53
Thanks: 7


Better Direction for Giaconda and a Better Future


This small biotech company based in Sydney has taken a new direction in further developing an Irritable Bowel Syndrome drug called Ibaconda. Ibaconda doesnt have a bigger dollar market share than Myoconda which is 2 Billion $US, Ibaconda market share is valued at 500 Million $US ...No#1

Myoconda was Giacondas lead drug and has just been sold for 1.5 million plus a 5% net royalty to Australian Medical Therapy Investments. At first I was a little surprised and disappointed at the sale for such a small amount of money. On the other hand the CEO has been trying to raise funding for the final stage for Myoconda for the pass 5 years with no success, with no cash in the bank this could not continue for ever.

I feel the CEO has taken Giaconda in a new better direction in a more marketable drug called Ibaconda which has a 27 million IBS suffers compared to Crohns disease sufferers of a million.

The problem with Ibaconda for Giaconda its in early stage of a clinical trial at stage IIa while Myoconda was at stage III. I really dont know how long it will take to get Ibaconda to stage III. I feel that this could take sometime as Im no expert on time lines for drug clinical trials but I feel that 12 month max to get to stage III if all goes well. According to Giaconda Ibaconda has a high success rate of 81% which is extremely promising.

Ibaconda Funding ..No#2
Since selling Myoconda Giaconda will have 1.5 Million to develop Ibaconda to go to market. If you read the announcement on March 2nd 2010 third paragraph

Under the Collaborative Research Agreement the CDD will assume control and the cost of the ongoing research and development of Ibaconda.

I feel that funding drug development in the pass was a major problem for Giaconda. Now with more funds things are looking more promising.


Future Share Prices
The top 20 share holders which have 85.2% last year it was 85.4% of the shares (one of the most tightly held shares in the ASX) It would not take much to see the share price move quickly with a good Ibaconda development announcement. Looking at the share price of just $00.05c and little share low liquidity it would not take much to see an increase in the share price. For example Giaconda gained 116.7% (+7c) to 13c over in a week, and while only 190,900 shares were traded in all In September 09.

Giacionda is a LONG term share investment with a good a few announcement(s) share will not be $00.05c a share, if youre looking for a quick buck forget it wont happen over night with Giaconda. It would be interesting to see the share price in 12 months time. Oh! Yes I own shares in Giaconda

Ibaconda Review From Giaconda No#3

Finally, we published a poser that was accepted by the Digestive Disease Week annual convention in Chicago last June. This, of course, was peer reviewed and published in the abstracts of the meeting and it demonstrated very significant results for Ibacondas combination of olsalazine and colchicine. Margauxs group did a retrospective analysis of 12 patients who had been on the therapy for their constipation for up to 22 months and ALL OF THEM responded to it. For over 81% of these patients, their problem was completely resolved. This is exciting news for the large number of people who have constipation predominate Irritable Bowel Syndrome. The global data shows that 9% of the population suffers from constipation problems in IBS and that is a very larger number for any therapy.



About Irritable Bowel Syndrome
Irritable Bowel Syndrome is a functional bowel disorder characterized by symptoms including abdominal pain or cramping, bloating, diarrhoea and / or constipation. 10-15% of the world population suffers from IBS. The cause of IBS remains unknown. IBS may be either diarrhoea-predominant or constipation-predominant or alternating between both. Approximately 9% of the worlds population suffers from IBS with constipation symptoms. There is currently no effective treatment or cure for IBS. Therapy may vary from a change in diet to the use of various medications, such as laxatives or drugs that change the motility of the bowel.While such treatments relieve symptoms for some patients, a large proportion of patients continue to suffer.

Ibaconda - A combination therapy for Irritable Bowel Syndrome
Ibaconda is a combination of olsalazine and colchicine which has been identified as providing effective relief to patients with constipation-predominant IBS when used in combination. Olsalazine is an anti-inflammatory medication currently used to treat ulcerative colitis that produces a laxative effect. Colchicine is a drug that has also demonstrated some efficacy when used to treat the symptoms of constipation. Both of these drugs when used as a single agent are only moderately effective in some patients. When used together these drugs provide more effective relief of constipation than either of the two drugs used alone. It is on this basis that Giaconda contends that
this combination offers an effective treatment alternative for patients with constipation-predominant IBS. Results of the use of this treatment at the Centre for Digestive Diseases reinforce this concept and are being further quantified through research.


Source
No#1
Myoconda Ibaconda Market Share
Slide 11 Giaconda 2008 AGM
http://www.giacondalimited.com/pdfs/AGM%20presentation.pdf


Source
No#2
Ibaconda Funding
Slide 21 Page 21 Giaconda 2009 AGM
http://www.asx.com.au/asxpdf/20100302/pdf/31p13tq1vlwxzt.pdf

Source
No#3
Ibaconda Review
Slide 21 Page 21 Giaconda 2009 AGM
http://www.asx.com.au/asxpdf/20091124/pdf/31m8f4bcn6g1l7.pdf

Information on Drug Clinical Trials
http://en.wikipedia.org/wiki/Clinical_trial

Wally




--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: rosskend  william  
 
wallyoff
post Posted: Dec 28 2009, 01:12 PM
  Quote Post


Posts: 53
Thanks: 7


In Reply To: william's post @ Feb 23 2009, 07:56 AM

The Last Post or is it!

Well its been over 12 months since my last post for Giaconda and things dont look to crash hot for this little Bio Company based in Sydney.

I went to this years AGM in November and there were 6-8 shareholders at the meeting. A well presented Power Point presentation on there lead drug Myoconda. Very much the same presentation as last years Blah! Blah!

Good news, a resolution was passed for the issue of 20 Million shares at 00.03c per share. This will give Giaconda approx $500,000 to $600,000 (according to the CEO) or approx 5-6 months of money for running the company. After that funding drys up I really dont know what is going to happen as they have been trying to find additional funding close to 2 years with no success. It came close to getting funding last year but that fell threw thanks to the GFC.

Looks like this company has been on life support for the last year and I dont see things improving in the near future for the following reasons

1. Aust dollar for too high for Foreign Inventors to fork out 30 million for final funding.
2. The CEO is now based in Canada as his Visa has run out and has to return home.

3. I tried to e-mail the CEO but the e-mail is not being delivered (Server is broken) Try and send an e-mail to Giaconda and you will get a return message. Mail server down for over three weeks!

Unable to deliver message to the following recipients, due to being unable to connect successfully to the destination mail server.


4. Tried calling the Head Office only received a message saying the usual leave a message and I will call you back, Blah, Blah! No return call.

If we dont get funding ASAP I think we are going to do our money on this one.

If funding is found that we are going to have to wait another 12 months for approval of Myoconda. Good news is if funding is found Im going to look very stupid and this share price of 00.06 per share will be a distant memory.

Im still holding and hoping for the best. Good luck to all.

Wally



--------------------
“If you want to get something done, always ask the busiest person”

Said 'Thanks' for this post: fraz2  
 
 


10 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING